Glaxo "Shakes Up" Alli Ad Strategy With New Agency
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's decision to reassign the advertising contract for its alli OTC weight-loss drug two years after the product's launch could point to a fundamental problem with the brand's message, according to Steven Brozak, an investment banker working with biotech, medical device and health care firms